Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2024 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology

New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness Findings consistent with another study recently published in the Journal of Comparative...
June 14, 2024 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association

THE WOODLANDS, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 84th Scientific...
May 29, 2024 07:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024

THE WOODLANDS, Texas, May 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies Global Healthcare Conference. Jeff Wade,...
May 14, 2024 07:00 ET | Source: Lexicon Pharmaceuticals, Inc.

New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

THE WOODLANDS, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data showing that INPEFA® (sotagliflozin), a...
May 09, 2024 07:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024

THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024....
May 02, 2024 16:05 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Commercial launch of INPEFA® (sotagliflozin) for Heart Failure continues to progress Resubmission of NDA for ZYNQUISTA™ (sotagliflozin) in Type 1 Diabetes expected mid-year 2024 Start-up ongoing for...
April 29, 2024 09:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals

THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats has provided notice of his retirement as chief executive...
April 29, 2024 07:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024

THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2024 financial results on Thursday, May 2, 2024 after the markets...
April 18, 2024 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Host 2024 Investor Day

THE WOODLANDS, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that senior company executives will be joined by leading physicians at the...
April 03, 2024 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

THE WOODLANDS, Texas, April 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner,...